Alimera Sciences Inc
ALIM.O- Latest Trade
- trading higher1.89USD
- 0
- 0.00%
- As of Mar 30 2023. Values delayed up to 15 minutes
- Today's Range
- -- - --
- 52 Week Range
- 1.30 - 7.92
- Previous Close
- 1.89
- Open
- 0.00
- Volume
- 37.00
- 3 Month Average Trading Volume
- 0.43
- Shares Out (Mil)
- 7.01
- Market Cap
- 13.68
- Forward P/E
- -0.82
- Dividend Yield
- 0.00
Key Statistics
2.33 mean rating - 3 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 0.25
- Price To Book (Quarterly)
- 0.00
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -63.47
- Return On Equity (TTM)
- -35.62
2021 (millions USD)
About Alimera Sciences Inc (ALIM.O)
Company Information
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.
Address
STE 290, 6120 WINDWARD PARKWAYALPHARETTA, GA
30005
United States
Industry
Biotechnology & Drugs
Executive Leadership
- C. Daniel Myers
- Non-Executive Chairman of the Board
- Richard S. Eiswirth
- President, Chief Executive Officer, Director
- Russell L. Skibsted
- Chief Financial Officer, Senior Vice President
- Philip Ashman
- Chief Operating Officer, Senior Vice President - Commercial Operations Europe
- David R. Holland
- Chief Marketing Officer, Senior Vice President - Corporate Communications and Managed Markets
- Michael Kaseta
- Director
- Adam Morgan
- Director
- Garheng Kong
- Independent Director
- Erin Parsons
- Independent Director
- Peter J. Pizzo
- Independent Director
- John Snisarenko
- Independent Director
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,969.60 | 0.14% |
| Copper | 788.00 | 0.79% |
| Brent Crude Oil | 78.84 | 0.72% |
| CBOT Soybeans | 1,481.25 | 0.27% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,027.81 | -- |
| Euro STOXX 50 | 4,283.81 | 1.24% |
| FTSE 100 | 7,620.89 | 0.75% |
| Nikkei 225 | 27,782.93 | 0.36% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes